Fernández J, Angeli P, Trebicka J, et al. - A multicenter, open-label trial, in which 118 patients with cirrhosis, non-spontaneous bacterial peritonitis (SBP) infections, and additional risk factors for poor outcome were randomized to receive antibiotics with albumin (study group; n = 61) or antibiotics alone (control group; n = 57), was conducted in order to, ascertain whether albumin should be administered to patients with infections not associated with SBP. In results from standard laboratory tests, serum markers of inflammation, circulatory dysfunction, or liver severity scores, no important variations at baseline between groups were noted. Nonetheless, in the study group, the combined prevalence of acute on chronic liver failure (ACLF) and kidney dysfunction was significantly greater, betokening greater baseline overall severity. No meaningful variation in the primary outcome across groups was observed. Only in the study group, circulatory and renal functions got better. In the study group, a notably greater proportion of individuals had a resolution of ACLF. A markedly lesser proportion of patients in the study group contracted nosocomial infections. Hence, in-hospital mortality in a randomized trial of patients with advanced cirrhosis and non-SBP infections was comparable between those who received albumin with antibiotics vs those who received only antibiotics (controls). Nevertheless, individuals who were given albumin were sicker at baseline and, a greater proportion had ACLF resolution and a lesser proportion had nosocomial infections during the follow-up period.